Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Charmacy Pharmaceutical Co., Ltd. Class H ( (HK:2289) ) has shared an announcement.
Charmacy Pharmaceutical Co., Ltd. has scheduled a board meeting for 27 March 2026 to review and approve the annual results of the company and its subsidiaries for the year ended 31 December 2025, along with their planned public release. The board will also consider whether to recommend the payment of a final dividend, a decision that could affect shareholder returns and signal management’s view of the group’s financial health.
The notice, issued over the signature of chairman Yan Jingbin in Shantou on 16 March 2026, underscores the company’s adherence to formal governance and disclosure practices required of Hong Kong-listed issuers. Investors will look to the forthcoming results and any dividend proposal for indications of operational performance and the company’s position within the competitive pharmaceutical market.
The most recent analyst rating on (HK:2289) stock is a Hold with a HK$6.00 price target. To see the full list of analyst forecasts on Charmacy Pharmaceutical Co., Ltd. Class H stock, see the HK:2289 Stock Forecast page.
More about Charmacy Pharmaceutical Co., Ltd. Class H
Charmacy Pharmaceutical Co., Ltd. is a pharmaceutical company incorporated in the People’s Republic of China and listed in Hong Kong under stock code 2289. The firm operates through a board comprising executive, non-executive and independent non-executive directors, reflecting a standard listed-company governance structure in the pharmaceutical sector.
Average Trading Volume: 10,300
Technical Sentiment Signal: Sell
Current Market Cap: HK$626.4M
See more insights into 2289 stock on TipRanks’ Stock Analysis page.